FDA approves Moderna's next-generation COVID-19 vaccine.

In an official statement, Moderna said the FDA has approved the mNEXSPIKE vaccine for individuals aged 12-64 with at least one underlying health risk factor.

On May 31, the U.S. Food and Drug Administration (FDA) approved Moderna's next-generation COVID-19 vaccine, mNEXSPIKE, for adults aged 65 and older.

This is the first vaccine to be approved by the FDA since the agency tightened its licensing standards.

In an official statement, Moderna said the FDA had also approved the mNEXSPIKE vaccine for individuals aged 12-64 with at least one underlying health risk factor.

This move comes as the U.S. Department of Health and Human Services (HHS) is increasing its oversight of the vaccine approval process.

Earlier on May 20, the FDA announced it would require pharmaceutical manufacturers to conduct enhanced trials of COVID-19 vaccines in healthy adults under 65 years of age if they want approval.

This means that the new vaccine will be primarily intended for the elderly and those at high risk.

mNEXSPIKE, which can be stored in the refrigerator instead of the freezer, helps extend shelf life and simplify distribution, especially in developing countries facing supply chain challenges during mass vaccination campaigns.

To date, the U.S. Centers for Disease Control and Prevention (CDC) continues to recommend that both healthy children and parents get vaccinated against COVID-19 to protect their health.

(VNA/Vietnam+)

Source: https://www.vietnamplus.vn/fda-phe-duyet-vaccine-phong-covid-19-the-he-moi-cua-moderna-post1041748.vnp